Deciphera Pharmaceuticals, Inc. (DCPH)
After hours:
| Previous close | 14.72 |
| Open | 14.67 |
| Bid | 14.20 x 200 |
| Ask | 14.27 x 300 |
| Day's range | 14.19 - 14.91 |
| 52-week range | 9.90 - 17.73 |
| Volume | |
| Avg. volume | 522,008 |
| Market cap | 1.15B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
WALTHAM, Mass., April 09, 2024--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16, 2024 at 11:30 AM ET.
- Business Wire
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
WALTHAM, Mass., February 27, 2024--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:
- Business Wire
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
WALTHAM, Mass., February 06, 2024--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.
